BioSpace News Archive

PDS Biotechnology Corporation announced the Canadian Intellectual Property Office has allowed patent number 2,876,656 titled, “Cationic Lipid Vaccine Combinations and Methods of Use,” governing composition of matter and uses for Versamune® in combination with PDS0301.

APIE Therapeutics (APIE Tx) , a preclinical regenerative medicines company, today announced the appointment of industry veteran, Ashwin Datt as CEO and a member of its Board of Directors.

TRACON Pharmaceuticals announced it has collected the previously announced arbitration award from I-Mab Biopharma.

STRATA Skin Sciences, Inc. announced the Journal of Clinical and Aesthetic Dermatology published a review and an expert perspectives article in the June 2023 Supplemental edition titled, “Photopneumatic Technology for the Treatment of Mild-to-Moderate Acne Vulgaris.”

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU).

Cingulate Inc. announced positive top-line results from its Phase 3 adult trial of its lead candidate, CTx-1301, a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder, upon approval from the U.S. Food and Drug Administration.

Longeveron Inc. announced today the appointment of Nataliya Agafonova, M. D., as the Company’s Chief Medical Officer (CMO), effective as of July 1, 2023.

Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce it dosed the first cohort of both male and female subjects with no serious adverse events in a Phase I/II urinary tract infection (UTI) clinical trial evaluating RECCE® 327 (R327) at faster infusion rates.

Daré Bioscience, Inc. today announced additional positive data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD).

Ocean Biomedical, Inc. announced that it is focusing its multi-pronged malaria program to address the chronic malaria crisis in sub-Saharan Africa while recognizing newly emerging global malaria challenges.